Recombinant Interferon α-2B Gel Combined with Lactobacillus as a Vaginal Capsule in Patients with Cervical High-Risk Human Papillomavirus

This study was performed to investigate the effects of Lactobacillus vaginal capsules combined with recombinant human interferon α-2b gel on clinical efficacy, vaginal microbial function indicators, vaginal microecological balance, inflammation levels, and drug safety in patients with persistent cervical high-risk human papillomavirus infection. Patients with human papillomavirus infection (n = 128) were randomly divided into control and observation groups of equal size. Patients in the control group were treated with recombinant human interferon α-2b gel alone. Patients in the observation group were treated with Lactobacillus vaginal capsules and human interferon α-2b gel. After treatment, the clinical efficiency, microbial function index, and human papillomavirus-DNA conversion rate of patients in the observation group were significantly higher than those in the control group. Further, pH, Nugent scores, human papillomavirus-DNA viral load, vaginal microecological dysregulation rate, and inflammation level were significantly lower than those in the control group. Lactobacillus vaginal capsules in combination with recombinant human interferon α-2b gel improved clinical outcomes and disease regression rates in patients with human papillomavirus infection, while also improving vaginal microecological balance and suppressing inflammatory responses.